News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Keryx (KERX) Announces Second Quarter 2017 Financial Results And Increased 2017 U.S. Product Sales Guidance



7/27/2017 10:42:47 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
BOSTON, July 27, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced its financial results for the quarter ended June 30, 2017. The company also reviewed its commercial progress with Auryxia and upcoming milestones.

“Our second quarter results reflect continued strong Auryxia prescription demand,” said Greg Madison, president and chief executive officer of Keryx. “This demand was largely driven by solid execution across our entire field team, which increased both breadth and depth of prescribing among physicians. With this momentum, we have increased our annual net Auryxia product sales guidance, reflecting improved confidence in our ability to bring this medicine to a greater number of people with chronic kidney disease (CKD) on dialysis this year.”

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES